{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:46:23Z","timestamp":1792320383349,"version":"4.4.0"},"reference-count":13,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2018,11,7]]},"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1136\/ejhpharm-2018-001752","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T17:15:16Z","timestamp":1543684516000},"page":"52-54","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome"],"prefix":"10.1136","volume":"27","author":[{"given":"Maria","family":"de Castro Julve","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT. Universitat Aut\u00f2noma de Barcelona, Sabadell, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Miralles Albors","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT. Universitat Aut\u00f2noma de Barcelona, Sabadell, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ortonobes Roig","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT. Universitat Aut\u00f2noma de Barcelona, Sabadell, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Vives","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT. Universitat Aut\u00f2noma de Barcelona, Sabadell, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Falgueras","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT. Universitat Aut\u00f2noma de Barcelona, Sabadell, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f2nica","family":"G\u00f3mez-Valent","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Parc Taul\u00ed Hospital Universitari. Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT. Universitat Aut\u00f2noma de Barcelona, Sabadell, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"key":"2025090221394461000_27.1.52.1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0352-7"},{"key":"2025090221394461000_27.1.52.2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/DDDT.S84667","article-title":"Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections","volume":"11","author":"Ferr\u00e1ndez","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2025090221394461000_27.1.52.3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-017-0601-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of oxazolidinones","volume":"57","author":"Roger","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2025090221394461000_27.1.52.4","unstructured":"EMA (European Medicines Agency). Summary of product characteristics: Sivextro (tedizolid) [Internet]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002846\/WC500184802.pdf (accessed 13 Apr 2018)."},{"key":"2025090221394461000_27.1.52.5","unstructured":"AEMPS (Spanish Agency of Medicines and Medical Devices). Summary of product characteristics. Zyvoxid (linezolid) [Internet]. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/64109\/FT_64109.html (accessed 13 Apr 2018)."},{"key":"2025090221394461000_27.1.52.6","doi-asserted-by":"publisher","DOI":"10.1086\/503839"},{"key":"2025090221394461000_27.1.52.7","first-page":"82","article-title":"European public assessment report\u00a0(tedizolid)","volume":"44","author":"Bay-mattawa","year":"2011","journal-title":"Sivextro"},{"key":"2025090221394461000_27.1.52.8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3949\/ccjm.83a.15129","article-title":"Serotonin syndrome: preventing, recognizing, and treating it","volume":"83","author":"Wang","year":"2016","journal-title":"Cleve Clin J Med"},{"key":"2025090221394461000_27.1.52.9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bph.14105","article-title":"Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome","volume":"175","author":"Rickli","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2025090221394461000_27.1.52.10","unstructured":"AEMPS (Spanish Agency of Medicines and Medical Devices). Summary of product characteristics. Fendivia (fentanyl). https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/68493\/FT_68493.html"},{"key":"2025090221394461000_27.1.52.11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/1742-6723.12521","article-title":"Serotonin toxicity caused by the interaction of fentanyl and serotonergic medications","volume":"28","author":"Armitage","year":"2016","journal-title":"Emerg Med Australas"},{"key":"2025090221394461000_27.1.52.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00431-13"},{"key":"2025090221394461000_27.1.52.13","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2018-001752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T04:39:52Z","timestamp":1756874392000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2018-001752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,18]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/ejhpharm-2018-001752"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2018-001752","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}